The global live cell imaging market size is expected to reach USD 2.8 billion by 2025 from an estimated value of USD 1.8 billion in 2020, growing at a CAGR of 8.8% during the forecast period. growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging.  

The growth in research funding and rising government funding and investment in regenerative medicine research will also support the market growth in the coming years. However, the high cost of high-content screening systems is limiting the overall adoption of these products. 

ccording to the WHO, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials. At the forefront of the COVID-19 outbreak, many researchers worldwide are engaged in the viral research of SARS-CoV-2, the virus that causes COVID-19. Live cell imaging systems, including advanced microscopy systems, help researchers investigate cellular behavior during viral research. 

The normalization of the global economy will slowly increase the demand for live cell imaging systems in non-COVID-related research activity labs, leading to market growth from the first quarter of 2021. Furthermore, players operating in the market are altering their strategies, for both long-term and short-term growth, by tapping the research market and developing innovative products to combat the pandemic. 

 The use of HCS makes the drug development process more time- and cost-efficient. Owing to these factors, the adoption of high-content screening for toxicity studies is expected to increase during the forecast period. This, in turn, is expected to drive market growth as live cell imaging is used in HCS to identify meaningful information from complex systems such as in vitro, in vivo, and ex vivo systems.  

Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163914483

High-content screening (HCS) instruments are equipped with advanced features and functionalities and are, therefore, priced at a premium. A confocal microscope, for instance, can cost more than USD 250,000, and a wide-field microscope can cost more than USD 100,000. Similarly, the InCell 2000 Analyzer system (from GE Healthcare) used in HCS costs around USD 240,000. 

Academic research laboratories find it difficult to afford such high-priced instruments as they have restricted budgets. The high price of these instruments is also a concern for several pharmaceutical companies as they require multiple HCS systems in their RD activities (thus increasing the total cost spent on these systems).  

In addition to the high procurement costs, the maintenance costs and several other indirect expenses increase the total cost of ownership of these instruments. This is one of the major factors limiting the adoption of live cell imaging instruments in clinical and research applications, especially in emerging countries.  

Cost savings and a lack of regulations are among the most important drivers boosting preclinical activities in China. The growing funding and investments in life science research, availability of highly skilled personnel, and a favorable regulatory environment are the other major factors supporting this trend. Moreover, currently, China has many CROs that provide preclinical and clinical research services to multinational pharmaceutical companies. 

Download PDF Brochure With Latest Edition @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

Running live cell imaging experiments successfully can be a major challenge. The conditions under which cells are maintained under microscopes decide the success or failure of the experiment. Therefore, maintaining living cells on slides is the most crucial part of the experiment. The cells used in experiments should be in good condition and function normally under a microscope in the presence of synthetic fluorophores or fluorescent proteins. 

Additionally, maintaining a constant cellular environment is very important during the experiment; the cells should be grown in culture media in a carbon dioxide incubator. Temperature also plays a crucial role in maintaining cell viability in a culture. Hence, as the cell viability and cellular environment are dependent on several specific requirements, the chances of a live cell imaging experiment being unsuccessful are high.  

The consumables segment, on the other hand, is expected to grow at the highest CAGR during the forecast period. The need for the frequent purchase of consumables is expected to play a key role in the growth of the consumables market during the forecast period.  

The high growth rate of this region can mainly be attributed to the factors such as the government initiatives for research on stem cell therapy, the rising prominence of regenerative medicine research, growth of preclinical/clinical research in China, favorable changes in foreign direct investment (FDI) regulations in the pharmaceutical industry in India.